1. South Korea Stocks

  2. •

    Health technology

  3. •

    Medical specialties
ToolGen Incorporated

ToolGen Incorporated

KKRX:199800
27,900.00
KRW
-600.00
(-2.11%)
-4,333.25EPS
335.07BMarket Cap
ToolGen Incorporated
KRX:199800
(Korea Stock Exchange)

Recent

price

27,900.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
KRW
320.26
413.83
276.72
567.81
179.22
170.74
106.94
228.93
93.09
137.16
109.12
148.41
211.85
Revenue per Share
31.47
-1,006.21
-541.96
-738.67
-1,248.17
-2,395.04
-2,231.76
-2,965.71
-2,276.02
-5,263.18
763.26
-4,176.31
-4,333.25
Basic EPS, GAAP
17.67
-423.54
-652.18
-862.56
-1,041.93
-1,635.38
-1,832.09
-2,213.68
-2,550.28
-2,684.02
-2,081.14
-2,347.94
-2,644.11
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
766.47
1,749.31
2,874.58
2,201.13
5,680.38
4,042.28
4,374.95
10,608.24
8,793.11
3,738.98
6,725.09
6,127.17
5,084.58
Book Value per Share
599.22
1,617.29
2,841.89
2,168.36
5,623.79
3,969.09
3,969.11
10,292.97
8,503.79
3,473.43
6,494.48
5,928.65
4,895.89
Tangible Book Value per Share
5
5
6
6
6
7
7
7
8
8
8
9
9
Basic Weighted Avg Shares
1,502
2,117
1,540
3,338
1,157
1,125
713
1,597
743
1,103
891
1,306
1,913
Sales/Revenue/Turnover
10.38
-10.21
-177.37
-121.7
-720.21
-1,434
-2,098.7
-1,297.54
-2,607.47
-1,548.61
-2,446.35
-1,782.04
-1,245.64
Operating Margin (%)
152
175
171
203
228
1,710
793
875
1,075
1,542
1,833
1,776
1,808
Depreciation Expense
148
-5,147
-3,017
-4,343
-8,057
-15,781
-14,882
-20,692
-18,177
-42,340
6,232
-36,764
-39,122
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
9.83
-243.15
-195.85
-130.09
-696.46
-1,402.71
-2,086.95
-1,295.49
-2,444.93
-3,837.21
699.45
-2,814.07
-2,045.48
Profit Margin (%)
4,409
7,565
13,682
7,452
30,824
20,538
19,363
73,504
52,808
64,464
34,766
27,039
16,665
Working Capital
2,015
800
800
- -
- -
54
61
20
1
60,409
117
88
84
LT Debt
3,753
9,576
16,886
12,988
36,986
26,770
29,891
84,663
70,469
30,095
58,436
55,851
46,500
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-26.79
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
10.82
- -
- -
Return on Capital (%)
- -
-77.23
-22.8
-29.08
-32.24
-49.51
-52.53
-36.13
-23.43
-84.21
14.08
-64.34
-77.36
Return on Common Equity (%)

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1,658
86
84
LT Borrowings
- -
- -
- -
LT Finance Leases
88
103
84
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
9
9
9
Market Capitalization
525,395
483,733
335,068

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
31,228
25,785
19,932
Cash, Cash Equivalents & STI
30,178
24,632
19,059
Accounts Receivable, Net
115
186
217
Inventories
- -
- -
- -
Total Current Liabilities
4,189
2,358
3,266
Payables & Accruals
- -
- -
- -
ST Debt
1,658
86
84
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
42.1%
39.79%
-4.42%
Free Cash Flow
27.81%
12.93%
21.64%
Net Income, GAAP
-46.66%
-128.97%
-689.94%
Sales/Revenue/Turnover
13.11%
29.27%
46.63%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
121
159
441
170
891
2025
129
185
631
404
1,306
2026
391
487
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-615.73
-766.22
-640.32
2,783.93
763.26
2025
-511.47
-504.58
-624.8
-2,466.28
-4,176.31
2026
-482.98
-741.63
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
ToolGen Incorporated ToolGen Incorporated (199800.KQ), a biotechnology company founded in 1999 and headquartered in Seoul, South Korea, develops advanced genome editing technologies, including clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 gene scissors, ribose nucleic acid (RNA)-guided endonucleases (RGEN), and deoxyribonucleic acid (DNA)-directed RGEN (dRGEN) for precise editing of genetic information in microbial, plant, animal, and human cells; it also provides genome engineering services, patent licensing and monetization, therapeutics for genetic and rare diseases, and seed businesses focused on high-value crops such as stress-tolerant, pest-resistant soybeans using CRISPR-Cas9 technology. The company operates primarily in South Korea with approximately 80 employees and targets biomedicine, agriculture, and research sectors through strategic collaborations with academia and industry partners. Recent developments include a strategic cross-license agreement with GenEditBio Limited in November 2025 to combine ToolGen's CRISPR-Cas9 platform with GenEditBio's lipid nanoparticle delivery systems for in vivo genome-editing therapeutics like GEB-200, following successful proof-of-concept studies in non-human primates; additionally, ToolGen filed a patent infringement lawsuit against Vertex Pharmaceuticals in the United Kingdom in April 2025 over the genome editing therapy CASGEVY.